Hongxiu Ning
About Hongxiu Ning
Hongxiu Ning is a Director at CERo Therapeutics, Inc., with over 10 years of experience in stem cell research and 5 years in oncology studies. He has held various scientific positions at notable organizations, including Pfizer and Allogene Therapeutics, and emphasizes effective communication within teams.
Current Role at Cero Therapeutics
Hongxiu Ning serves as the Director at Cero Therapeutics, Inc. since 2021. In this role, he focuses on developing a consistent and robust therapeutic cells manufacturing process. His leadership is integral to advancing the company's initiatives in cell therapy.
Previous Experience at Allogene Therapeutics
Prior to his current position, Hongxiu Ning worked at Allogene Therapeutics as a Principal Scientist from 2019 to 2021. He also held the role of Senior Scientist for 7 months in 2018. His tenure at Allogene Therapeutics involved significant contributions to the development of innovative therapeutic solutions.
Professional Background in Pfizer
Hongxiu Ning has extensive experience from his time at Pfizer, where he worked as a Scientist from 2015 to 2016 and as a Senior Scientist from 2016 to 2018. His roles at Pfizer contributed to his expertise in the pharmaceutical industry, particularly in the development of therapeutic strategies.
Academic and Research Background
Hongxiu Ning's academic background includes a Doctor of Philosophy (Ph.D.) in Oncology and Cancer Biology from Tsinghua University. He also completed a postdoctoral fellowship at UCSF Medical Center from 2005 to 2010, which laid the foundation for his research in stem cells and oncology.
Expertise in Stem Cells and Oncology
With over 10 years of experience in stem cell research and 5 years in oncology studies, Hongxiu Ning has developed a strong foundation in these fields. His focus on communication and feedback within teams enhances collaborative efforts in research and development.